Peter Thiel-backed ATAI is preparing to go to Nasdaq, as interest in psychedelics reaches fever pitch
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The team behind ATAI Life Sciences has ratcheted up momentum over the last few months, and now they’re looking to capitalize with an IPO.
Backed by billionaire Peter Thiel, ATAI filed its SEC paperwork late Tuesday and outlined its plans to take its portfolio of experimental psychedelic medicines to Nasdaq. They’ve listed a $100 million raise for now, though that figure has commonly proved to be a mere placeholder during the biotech boom and the company could end up raising much more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.